Professional background

Jonathan Ledermann joined UCL and UCL Hospitals in 1990. He is professor of medical oncology in the UCL Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre. He is an honorary consultant in medical oncology at UCLH. He trained in internal medicine and medical oncology in London and Toronto, Canada.

He specialises in gynaecological cancer treatment and research and has led many national and international clinical trials. He has held leadership positions in National and International research organisations, is a NIHR senior investigator and fellow of the Academy of Medical Sciences. He is vice president of ESGO (European Society of Gynaecological Oncology) and deputy editor for ESMO gynaecological cancer guidelines committee. He is chair of the GICG rare tumour working party.

He has been on council of BGCS, chair of the non-surgical subgroup of BGCS and a member of Council of IGCS. He was formerly chair of the NCRI gynaecological cancer group and ESMO gynaecological cancer educational committee and a member of the EMA specialist advisory committee. He is on the editorial board of several cancer journals and has published widely on his research, and given lectures at many international meetings.

Research interests

  • Cancer clinical trials- leadership of an International cancer trials centre with expertise in design and development of trials
  • Clinical trials in gynaecological cancers with specific interests in targeted therapies and immunotherapy

Publications

1 Gourley C, Balmana J, Ledermann JA, et al. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. J Clin Oncol 2019;37(25):2257-69

2 Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. Ann Oncol. 2019 30:1080-87

3 Coleman RL, Oza AM, Lorusso D et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949-61.

4 Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 2016;17(11):1579-89

5 Ledermann JA, Embleton AC, Raja F, et al Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066-74

6 Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274-84

7 Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014;384(9951):1376-88

8 Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61

9 Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New Engl J Med. 2012;366(15):1382-92

10 Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-96